Case Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.

Size: px
Start display at page:

Download "Case Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute."

Transcription

1 Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center April 28, 2017 Case Presentation 64 year old man Ischemic CM s/p CABG x 2 in past (last 3 years ago) Severely depressed LVEF on echo 1 year ago Symptomatic HF first in 2012 but stabilized on medications Now admitted with SOB x 1 week, no chest pain, weight increased 10 lbs Outpatient medications include carvedilol 6.25 mg bid; Enalapril 5 mg bid; aldactone 12.5 mg/day, lasix 40 mg bid

2 Case (continued) Pertinent admission data BP 100/74, HR 98, JVD 14 cm, lungs clear,? S3, 2+ edema, warm extremities Na 135, BUN 45, Cr 1.5 (3 months ago 1.3), ProBNP 2500 Rx BBL dose reduced; IV furosemide 80 mg bid Makes 1 L urine overnight and AM Cr rises to 1.8 Types of Cardiorenal Syndrome (CRS) Type CRS type 1 (acute) CRS type 2 (chronic) CRS type 3 (acute reno-cardiac syndrome) CRS type 4 (chronic reno-cardiac syndrome) CRS type 5 (secondary) Definition Abrupt worsening of cardiac function leading to kidney injury Chronic abnormalities in cardiac function causing progressive chronic kidney disease Abrupt worsening of renal function causing acute cardiac disorder (e.g. HF, arrhythmia, pulmonary edema) Chronic kidney disease contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of cardiovascular events Systemic condition causing both cardiac and renal dysfunction

3 Worsening Renal Function in HF Outline Epidemiology Causes of AKI in Heart Failure Management of AKI in Heart failure Meta-analysis: Worsening Renal Failure is Associated with Mortality (n=49,890) Damman, EHJ, 2014

4 Renal Function as Important as LVEF (CHARM) Multivariable HR for Risk of CV Death or HF Hospitalization Hillege, Circ, 2006 Improving Renal Function (Cr fall 0.3) is Also a Risk Factor for Adverse Outcomes (before You Consider WRF as a Surrogate Endpoint ) Cr DOSE Trial (NHLBI); N= x 2 factorial High vs Low dose diuretic; Bolus vs. Continuous infusion Brisco, JCF, 2016

5 Persistently Improved Renal Function (IRF) and Outcome U of Penn 903 patients discharged for CHF IRF = 20% improvement GFR 31% have IRF No IRF Persistent IRF (at D/C) Transient IRF (not at D/C) Testani, JCF, 2011 Outline Worsening Renal Function in HF Epidemiology Causes of WRF in Heart Failure Baseline renal function Systemic venous congestion Fall in systemic blood pressure Relative degrees of Right vs. Left congestion Management of AKI in Heart failure

6 Meta-analysis: Risk Factors for Worsening Renal Failure (n=49,890) Damman, EHJ, 2014 Baseline Renal Function is Associated with Risk of Worsening Renal Function (WRF): Meta-Analysis % Patients who Develop WRF Area of circle is proportional to sample size of cohort Baseline Serum Cr (mg/dl) Damman, J Card Failure, 2007

7 Distribution of CVP and its Curvilinear Relationship with egfr 2,557 patients with right heart catheterization Damman, JACC, 2009 Venous Congestion and Worsening Renal Function (Cr 0.3) CVP < 8 CVP 8-16 CVP CVP > patients, Cleveland Clinic Advanced, decompensated HF PA catheter Mullens, JACC, 2009

8 Venous Congestion, not CI, Associated with Worsening Renal Function AUC = 0.73 (p<0.001) Mullens, JACC, 2009 Cardiac Index is Not Driver of Worsening Renal Function in Heart Failure

9 CVP and Renal Dysfunction: Old Lessons Relearned Winton, J Physiology, 1931 If the blood pressure in the renal vein is raised above 10 mm Hg, it retards the urine flow. Firth, Lancet, 1988 Isolated perfused rat kidney GFR (ml/min) Venous Pressure (mm Hg) *

10 VMAC: Systemic Venous Congestion Not Associated with Worsening Renal Function N=238 Cr>0.3 up to 14 days Adapted from Aronson, Eur J Heart Fail, 2013 Larger Drop in Systolic Blood Pressure Contributes to Worsening Renal Failure Pre-RELAX-AHF N=234 Relaxin Voors, Eur J of Heart Fail, 2011

11 Decrease in MAP Associated with Worsening Renal Function Cleveland Clinic N=434 ADHF Right heart cath Dupont, Eur J Heart Fail, 2013 Relative Degree of Right to Left-Sided Congestion: RAP/PCWP ratio and Renal Dysfunction

12 Distribution of RAP/PCWP Ratio in the ESCAPE Trial Drazner et al, Circ HF, 2013 Concordant e.g., RA 11/PCWP 22 Drazner et al, Circ HF, 2013

13 Concordant e.g., RA 11/PCWP 22 RAP/PCWP<1/3 Compensated RV e.g., RA 5/PCWP 30 Drazner et al, Circ HF, 2013 Concordant e.g., RA 11/PCWP 22 RAP/PCWP<1/3 Compensated RV e.g., RA 5/PCWP 30 RAP/PCWP>2/3 Right-Left Equalizer e.g., RA 20/PCWP 24 Drazner et al, Circ HF, 2013

14 Compensated RV Pattern: Low RAP/PCWP Has Smaller RV Drazner, Circ HF, 2013 Compensated RV Pattern: Low RAP/PCWP Has Smaller RV Drazner, Circ HF, 2013

15 Sub-phenotyping HF by RAP/PCWP ratio Compensated RV pattern Low RAP/PCWP ratio: low RAP with high PCWP Erroneously believe patient is compensated Right-Left equalizer High RAP/PCWP ratio: RAP is higher than expected for given PCWP Over-diuresis? renal failure, worse outcome RAP/PCWP Ratio and Renal Function in Advanced Heart Failure Study N Association Cardiac Transplant Research Database 4079 Lower CrCL ESCAPE 215 Lower CrCl Cleveland Clinic 367 Lower egfr Drazner, J Ht Lung Transplant, 2012 Drazner, Circ Heart Failure, 2013 Grodin, AHJ, 2015

16 Increasing RAP/PCWP Quartile is Associated with Reduced egfr Grodin, AHJ, 2015 Increasing RAP/PCWP Quartile is Associated with Reduced egfr Independent of RAP in multivariable analysis Grodin, AHJ, 2015

17 Outline Worsening Renal Function in HF Epidemiology Causes of WRF in Heart Failure Management of AKI in Heart failure Outline Worsening Renal Function in HF Epidemiology Causes of AKI in Heart Failure Management of AKI in Heart failure Does all AKI indicate a need to change therapy? Failed strategies Proposed clinical approach

18 Modifiers of Prognosis Associated with Worsening Renal Function Hemoconcentration (decongestion) Clinical congestion NT-proBNP Medications which block RAAS Modifiers of Prognosis Associated with Worsening Renal Function Hemoconcentration (decongestion) Clinical congestion NT-proBNP Medications which block RAAS Assess clinical context

19 Hemoconcentration During Hospitalization is Associated with Worsening Renal Function Testani, Circ, 2010 In Support of Decongestion: Hemoconcentration is Favorable Prognostic Sign Hemoconcentration Hemoconcentration 2 of 3 of Delta: Hct Albumin Total protein No Hemoconcentration Testani, Circ, 2010

20 Worsening Renal Function in Presence of Hemoconcentraction May Not Be Adverse Risk Factor WRF, + Hemoconcentration No WRF, + Hemoconcentration No WRF, No Hemoconcentration WRF, no Hemoconcentration Testani, Eur J Heart Fail, 2011 Worsening Renal Function in Setting of Low NT-proBNP May Not Increase Risk PROTECT; N=151 RCT: Usual vs. NTproBNP guided WRF = any decrease in GFR by 3 months CV event = Worsening/hosp. HF, ACS, CV Death, Cerebral ischemia, Ventricular arrhythmia Ibrahim, JCF, 2017

21 Discharge Signs of Congestion Modifies Risk of Worsening Renal Function No WRF, + Congestion WRF, No Congestion No WRF, + Congestion WRF, + Congestion N=599 HF admissions Congestion: 1 or more signs of fluid overload at discharge WRF: Increase Cr 0.3 mg/dl Metra, Circ Heart Fail, 2012 Modifiers of Prognosis Associated with Worsening Renal Function Hemoconcentration (decongestion) Clinical congestion NT-proBNP Medications which block RAAS

22 Meta-analysis: RAAS Initiation Reduces Mortality Even in Setting of Worsening Renal Function EPHESUS RALES SAVE SOLVD VaL-HeFT Clark, EHJ, 2013 Worsening Renal Function After ACEi is Not Associated with Increased Mortality (SOLVD) Enalapril, WRF Enalapril, No WRF Placebo, No WRF Placebo, WRF Testani, Circ Heart Fail, 2011

23 Worsening Renal Function with Sprionolactone Use is Not Associated with Mortality (RALES) Vardeny, JACC, 2012 However

24 Worsening Renal Function Following ARB in HFPEF Is Associated with Adverse Outcomes Damman, JACC, 2014 Worsening Renal Function with RAAS inhibitor: HFrEF vs. HFpEF WRF more common with RAAS inhibitor (13% vs 9%) True in both HFrEF and HFpEF WRF with RAAS-inhib HFrEF HR 1.19 ( ) HFpEF HR 1.78 ( ) WRF with Placebo HR 1.48 ( ) HR 1.25 ( ) P interaction Postulated: Difference due to lack of benefit of RAAS inhibitor in HFpEF

25 Outline Worsening Renal Function in HF Epidemiology Causes of WRF in Heart Failure Management of AKI in Heart failure Does all AKI need to change therapy? Failed strategies Proposed clinical approach Failed Therapies for Renal Protection Nesiritide Dopamine Ultrafiltration Adenosine A 1 receptor antagonist Continuous loop diuretics Ularitide (synthetic urodilatin; TRUE-AHF) Serelaxin (human relaxin 2; RELAX-AHF2)

26 Can Echo and BNP Guided Therapy Reduce Risk of Renal Failure in HF? Multicenter observational outpatient study in Italy N=1137 (570 used Echo/BNP and 567 Clinical) Death or Worsening Renal Function Daily Furosemide dose Simioniuc, IJC, 2016 Can Echo and BNP Guided Therapy Reduce Risk of Renal Failure in HF? Multicenter observational outpatient study in Italy N=1137 (570 used Echo/BNP and 567 Clinical) Daily Furosemide dose Await GUIDE-IT Simioniuc, IJC, 2016

27 Outline Worsening Renal Function in HF Epidemiology Causes of WRF in Heart Failure Management of AKI in Heart failure Does all AKI need to change therapy? Failed strategies Proposed clinical approach Proposed Approach for Worsening Renal Function in Decompensated HF Lack of evidence base Look for alternative causes Nephrotoxins (NSAIDs, contrast) Interstitial nephritis (Abx, urine eosinophils) UTI Hydronephrosis Bladder outlet obstruction (amyloid/neuropathy)

28 Proposed Approach for Worsening Renal Function in Decompensated HF Lack of evidence base Look for alternative causes Assess clinical context Severity? (Cr 1.7 or 3.5) Responding to diuretics? Hemodynamics by clinical examination Congested? Right, Left, Both? Perfused? Blood pressure (manual check) Other modifiers Hemoconcentration NT-proBNP RAAS blocker Proposed Clinical Approach for Acute Kidney Injury in Decompensated HF Scenario: Clinically congested, significant in Cr, no alternative cause, not adequately diuresing despite escalation of diuretics Consider: Reduction of BP lowering medications including RAAS inhibitors and BBL Invasively measure hemodynamics Estimation of perfusion adequacy often wrong R>L congestion Inotropes/advanced HF therapies

29 ACC/AHA 2013 CHF Guidelines and PA Catheter (Class IIa- LOE C)..can be useful for carefully selected patients with acute HF who have persistent symptoms despite empiric adjustment of standard therapies and: whose fluid status, perfusion, or SVR or PVR is uncertain whose SBP remains low or is associated with symptoms despite initial therapy whose renal function is worsening with therapy who may require parenteral vasoactive agents who may need consideration of mechanical support/transplantation Summary Worsening renal function in HF associated with adverse outcomes (like low LVEF) Cannot be surrogate (improved renal function also unfavorable) Risk factors Baseline Cr Decrease in BP Age Disproportionate R to L congestion Treatment No evidence base Look for alternative causes Assess clinical context (decongested, probnp, hemoconcentration, maybe RAAS blocker) Sick patient: reduce RAAS/BBL, Right heart cath?

30

Heart Failure and Renal Disease Cardiorenal Syndrome

Heart Failure and Renal Disease Cardiorenal Syndrome Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National

More information

Pivotal Role of Renal Function in Acute Heart failure

Pivotal Role of Renal Function in Acute Heart failure Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS

More information

Cardio-Renal Syndrome in Acute Heart Failure:

Cardio-Renal Syndrome in Acute Heart Failure: Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine

More information

Recognizing and Treating Patients with the Cardio-Renal Syndrome

Recognizing and Treating Patients with the Cardio-Renal Syndrome Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts

More information

Overcoming the Cardiorenal Syndrome

Overcoming the Cardiorenal Syndrome Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland

More information

Practical Points in Cardiorenal Syndrome

Practical Points in Cardiorenal Syndrome Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok

More information

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center

More information

Heart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA

Heart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to

More information

Management of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University

Management of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University Management of Advanced Systolic Heart Failure Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University American College of Cardiology Foundation (ACCF) American Heart Association

More information

Management of Acute Heart Failure

Management of Acute Heart Failure Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.

More information

State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.

State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. Heart Failure Exacerbates Renal Insufficiency ADHERE Registry: Prevalence of CKD by egfr

More information

Management of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU

Management of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU Management of acute decompensated heart failure and cardiogenic shock Arintaya Phrommintikul Department of Medicine CMU Acute heart failure: spectrum Case 64 y/o M with Hx of non-ischemic DCM (LVEF=25-30%)

More information

The Cardiorenal Syndrome in Heart Failure

The Cardiorenal Syndrome in Heart Failure The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic

More information

State of the Art: acute heart failure Is it just congestion?

State of the Art: acute heart failure Is it just congestion? ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456

More information

Cardiorenal Syndrome

Cardiorenal Syndrome SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal

More information

How to define the target population?

How to define the target population? Heart Failure 2011 22-24 May. Gothenburg, Sweden Mortality or morbidity as target in acute heart failure trials How to define the target population? Marco Metra, Brescia The Burden of Acute HF Acute HF

More information

CASE STUDIES IN ADVANCED HEART FAILURE

CASE STUDIES IN ADVANCED HEART FAILURE CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING

More information

Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial

Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Background AHF + Renal

More information

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17 Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies

More information

Heart Failure Guidelines For your Daily Practice

Heart Failure Guidelines For your Daily Practice Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine

More information

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies

More information

ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014

ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy

More information

Behandeling van Hartfalen: over 5 jaar

Behandeling van Hartfalen: over 5 jaar Behandeling van Hartfalen: over 5 jaar Adriaan Voors, cardioloog UMCG Over 5 jaar Heart Failure Treatment in 5 Years HFrEF: best evidence, biggest pipeline Entresto Omcamtiv LVAD: destination therapy HFrEF:

More information

Monitoring of Renal Function in Heart Failure

Monitoring of Renal Function in Heart Failure Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,

More information

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received

More information

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF

More information

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University

More information

LITERATURE REVIEW: HEART FAILURE. Chief Residents

LITERATURE REVIEW: HEART FAILURE. Chief Residents LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity

More information

Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF

Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure Barry M. Massie Professor of Medicine UCSF DISCLOSURES Consulting fees: Merck-Novacardia Novartis Bristol Myers Squibb

More information

WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine

WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data Safety Monitoring Board SOPRANO (J&J), EVALUATE-HF

More information

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate

More information

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical

More information

Updates in Congestive Heart Failure

Updates in Congestive Heart Failure Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk

More information

Treating HF Patients with ARNI s Why, When and How?

Treating HF Patients with ARNI s Why, When and How? Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor

More information

Pearls in Acute Heart Failure Management

Pearls in Acute Heart Failure Management Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:

More information

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor

More information

THE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.

THE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D. THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios

More information

Cardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium

Cardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium Cardiorenal syndrome Sofie Gevaert Ghent University Hospital, Belgium Disclosures Consultancy Astra Zeneca Boegringer MSD Novartis 68 y old man, ADHF ICMP, ejection fraction 35 %: progressive dyspnea,

More information

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the

More information

Acute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra

Acute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

Objectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney

Objectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the

More information

Heart-failure or Kidney Failure?

Heart-failure or Kidney Failure? Heart-failure or Kidney Failure? Dr Ajith James Consultant Nephrologist Barts Health and BHRUT Mr AR 65 yrs Case Type 2 DM, IHD-MI 1998, 2003. PCI x 3. CABG 2008, HT CCF with LVEF 30% 2014. NYHA Class

More information

Ramani GV et al. Mayo Clin Proc 2010;85:180-95

Ramani GV et al. Mayo Clin Proc 2010;85:180-95 THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation

More information

Natriuretic Peptide Guided Therapy for Heart Failure

Natriuretic Peptide Guided Therapy for Heart Failure Natriuretic Peptide Guided Therapy for Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Duke Clinical Research Institute Disclosures Research Grants

More information

Intravenous Inotropic Support an Overview

Intravenous Inotropic Support an Overview Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)

More information

WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS

WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS George Bakris, MD, FASH, FAHA, FASN Professor of Medicine Director, Comprehensive Hypertension Center

More information

Heart Failure A Disease for the Internist?

Heart Failure A Disease for the Internist? Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices

More information

Biomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland

Biomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following

More information

The Art and Science of Diuretic therapy

The Art and Science of Diuretic therapy The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload

More information

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response

More information

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center

More information

HFpEF. April 26, 2018

HFpEF. April 26, 2018 HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes

More information

Heart Failure: Guideline-Directed Management and Therapy

Heart Failure: Guideline-Directed Management and Therapy Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the

More information

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G. Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center

More information

Diastolic Heart Failure Uri Elkayam, MD

Diastolic Heart Failure Uri Elkayam, MD Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A

More information

Congestive Heart Failure: Outpatient Management

Congestive Heart Failure: Outpatient Management The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy

More information

Medical Management of Acute Heart Failure

Medical Management of Acute Heart Failure Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training

More information

Beyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015

Beyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015 Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid

More information

Aldosterone Antagonist. Hyd/ISDN*

Aldosterone Antagonist. Hyd/ISDN* Μedical management of heart failure: Update 2014 Dr John T Parissis Attikon University Hospital Athens, Greece Disclosures: Received honoraria as consultant or research grants by Orion- Pharma, Servier,

More information

Cardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Cardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular

More information

Natriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA

Natriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,

More information

Heart Failure. Jay Shavadia

Heart Failure. Jay Shavadia Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary

More information

Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials

Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology

More information

HFpEF, Mito or Realidad?

HFpEF, Mito or Realidad? HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY

More information

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G. Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center

More information

Outline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Outline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G. Chronic Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center Scientific

More information

9/14/2017 HEART FAILURE IN OBS NO RELEVANT DISCLOSURES IRRELEVANT DISCLOSURES OBJECTIVES WHY HEART FAILURE

9/14/2017 HEART FAILURE IN OBS NO RELEVANT DISCLOSURES IRRELEVANT DISCLOSURES OBJECTIVES WHY HEART FAILURE HEART FAILURE IN OBS Matthew Wheatley MD, FACEP Grady Memorial Hospital Emory University School of Medicine NO RELEVANT DISCLOSURES 52 y.o. female with HTN, DM and CHF presents with DIB. She states she

More information

The ACC Heart Failure Guidelines

The ACC Heart Failure Guidelines The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA

More information

Sliwa et al. JACC 2004;44:

Sliwa et al. JACC 2004;44: TREATMENT OF ADVANCED HEART FAILURE HEART DISEASE IN KENTUCKY Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac

More information

Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure

Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure Item Type info:eu-repo/semantics/article Authors Hernández, Adrian V. Citation Eur Heart J (2014) 35

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

Implementing the CardioMEMS HF System into the Management of Heart Failure Patients

Implementing the CardioMEMS HF System into the Management of Heart Failure Patients Implementing the CardioMEMS HF System into the Management of Heart Failure Patients Robert W. Hull MD FACC Associate Professor of Medicine WVU Heart Institute Co-director, Arrhythmia Service Director,

More information

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What

More information

Cardiorenal Biomarkers and Heart Failure. Nicholas Wettersten, MD April 7 th, 2017

Cardiorenal Biomarkers and Heart Failure. Nicholas Wettersten, MD April 7 th, 2017 Cardiorenal Biomarkers and Heart Failure Nicholas Wettersten, MD April 7 th, 2017 Disclosures Still none, but looking for some Acute Kidney Injury Biomarkers 547 in 2015 4112 as of March 2017 Case 1 60

More information

Management of chronic heart failure: update J. Parissis Attikon University Hospital

Management of chronic heart failure: update J. Parissis Attikon University Hospital Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure

More information

A patient with decompensated HF

A patient with decompensated HF A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,

More information

Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor

Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor New Strategies in the Management of Acute and Advanced Heart Failure Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University

More information

Journal Club PowerPoint Template. A Question of Therapy RCT

Journal Club PowerPoint Template. A Question of Therapy RCT Journal Club PowerPoint Template A Question of Therapy RCT 1 EBM Process Ask a well built (focused) clinical question Search for the best evidence to answer the question Critically appraise the evidence

More information

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from

More information

Beta-blockers in heart failure: evidence put into practice

Beta-blockers in heart failure: evidence put into practice Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald

More information

Ruolo dei Marcatori Bioumorali nello scompenso cardiaco

Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Head Emergency Medicine Sant Andrea Hospital Director Postgraduate School of Emergency Medicine Faculty od Medicine and Psycology Sapienza University

More information

The role of remote monitoring in preventing readmissions after acute heart failure

The role of remote monitoring in preventing readmissions after acute heart failure The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure

More information

Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction

Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo

More information

Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital

Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier

More information

Akash Ghai MD, FACC February 27, No Disclosures

Akash Ghai MD, FACC February 27, No Disclosures Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &

More information

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest

More information

ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD

ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with

More information

HEART FAILURE. Ali Mehr, MD, FACC

HEART FAILURE. Ali Mehr, MD, FACC HEART FAILURE Ali Mehr, MD, FACC Advanced Heart Failure and Transplant Cardiologist Director, Echocardiography Lab Phoenix VA Health Care System Associate Professor of Medicine University of Arizona, COM,

More information

Vitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0.

Vitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0. ALDOSTERONE ANTAGONIST IN HEART FAILURE WITH PRESERVED EJECTION FRACTION ABBREVIATIONS BMP: basic metabolic panel HPI: history of present illness CAD: coronary artery disease HR: heart rate PINHUI (JUDY)

More information

UPDATES IN MANAGEMENT OF HF

UPDATES IN MANAGEMENT OF HF UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion

More information

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College

More information

3/30/2010 ACUTE DECOMPENSATED HEART FAILURE. Robert E. Hobbs, MD CLEVELAND CLINIC. Year Patients in US (millions)

3/30/2010 ACUTE DECOMPENSATED HEART FAILURE. Robert E. Hobbs, MD CLEVELAND CLINIC. Year Patients in US (millions) ACUTE DECOMPENSATED HEART FAILURE Robert E. Hobbs, MD CLEVELAND CLINIC EPIDEMIOLOGY OF HEART FAILURE Patients in US (millions) 10.0 10 8 550,000 new cases annually 6 4 5 million Americans have HF; likely

More information

State of the Art Treatment - Hyponatremia, Heart Rate, et al

State of the Art Treatment - Hyponatremia, Heart Rate, et al State of the Art Treatment - Hyponatremia, Heart Rate, et al Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from

More information

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment

More information

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure

New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF

More information